{"id":1022784,"date":"2026-11-19T16:18:40","date_gmt":"2026-11-19T21:18:40","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/"},"modified":"2026-11-19T16:18:40","modified_gmt":"2026-11-19T21:18:40","slug":"azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/","title":{"rendered":"Azora Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">LOS ANGELES, Nov.  19, 2026  (GLOBE NEWSWIRE) &#8212; Azora Therapeutics, Inc. (NASDAQ: AZR) (the \u201cCompany\u201d), a biopharmaceutical company developing treatments for serious inflammatory diseases, announced today that the Compensation Committee of its Board of Directors granted an option to purchase 40,000 shares of the Company\u2019s common stock under the Azora Therapeutics, Inc. 2026 Employment Inducement Equity Incentive Plan (the \u201c2026 Inducement Plan\u201d) to one new non-executive employee as an inducement material to such person entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n<p align=\"justify\">The option award has an exercise price of $3.81 per share, the closing price of the Company\u2019s common stock on November 16, 2026, the effective date of grant, and has a ten-year term. The option award will vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments thereafter, subject to the recipient\u2019s continued service through each applicable vesting date. The option award is subject to the terms and conditions of the 2026 Inducement Plan and the terms and conditions of an option award agreement covering the grant.<\/p>\n<p>The 2026 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of the Company or its parent or subsidiaries, or following a bona fide period of non-employment, as an inducement material to such individuals\u2019 entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4).<\/p>\n<p align=\"justify\">\n        <strong>About Azora Therapeutics, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Azora Therapeutics\u00a0is a biopharmaceutical company focused on developing treatments for serious inflammatory diseases. The company was launched out of Stanford University after being incubated in the translational medicine SPARK program. Azora owns worldwide royalty-free rights to its technology, which is based on the development of oral agonists of the aryl hydrocarbon receptor. Azora\u2019s lead program is AT177, a proprietary colon-targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure, in development for ulcerative colitis. More information on Azora can be found on the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rFbZkmg8r4848Tofei06u8pzn0I2QbIPwz-YCOjIzwvopunbIvycVUvWtVxU3wwV9EeBC57S6Pdv3kDnNtwFfDwR1tHv2Zxwh90nKrDfg0dg11jmPPk9YJ9C89LWPqNwowrrTJyhl0lkDehmioZ1jLrRU7J8vF6Sxpuz17YkPmJTMnOCTkUseIBn6wdpGM7qLXEkiTNFJj3HTZslleAxVcH0VVRrefbRJ8y8M54XTQpCFj4O5j7BDYaw_pP2Sn9pOL4MgenykvVHKv-XXmxud07k8XEFjdBTgwKIa2gTncA=\" rel=\"nofollow\" target=\"_blank\">www.AzoraTherapeutics.com<\/a>.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong>\n      <\/p>\n<p>Mike Moyer<br \/>Managing Director<br \/>LifeSci Advisors, LLC<br \/>Phone: (617) 328-4326<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jvO-b2gzztS-GZrzxzNpM79FZTKbevOTZpG0QqtnJ7zT7opR1sVl-8thVB0Jpi7fgVlMA3HsGFYAg7pWor2_QIngoVHyGgdUlj33tUQ9Q9NsQXBz9oJzYEO3nn48C54V\" rel=\"nofollow\" target=\"_blank\">mmoyer@lifesciadvisors.com<\/a>\u00a0<\/p>\n<p>\n        <strong>Media Contact:<\/strong>\n      <\/p>\n<p>Ashley Biladeau<br \/>Inizio Evoke Comms<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=igQaQsl2UJj9NdtUlTnOlqJdHcjdjwqfmBMoE0fxAeIwjdfh1_utD-3pxmx2DpGoTNa2hdfsqf5AAAO55u0WImrg0MFjDmnziC8N_Oo2JfTZ3xABa2cEXG1zk3EvAqkj4w4O4919og7TtVzV2ZH1SQbw8Kf5v3YNJFHu3HdePzKphRs5At6w51KIYRAyfoUZWebq5LHnorOpeoFoGl4vIVsVHWTrsdc4CYkCADsMR5CMyaPHPpYBtYs7nGXv6B6iP01S4p338kjdgdFsHnBFMxXtQ0HkNtbXkAcULvb4MjIGJa3xzy6MGWNWAcE-hbAimNh3dfAlG29HtI4M40UrIjFVyB4tH9mR5ahYEiSbaxwn-y2B4yfzyvzPogAYF3OvUDPzxiceS1bhc8ZSpG7QjcUnkJKJEAW35i8_KescBoMWjkFRA0vtUyTO5xAzrD3j-WdGngtp-gmJYqNz0l0HnG9VjLN69HRiruN0ze2kRValehk6FRljg7711ncnVn44wD2rmCJ4wjIu1RKfXvhgsEuxY2rQwzd5gHEpYD3k3hkqbeT64cavO5_IaaMYg85yP2r7mOrGcSonoVR3DFuURQ==\" rel=\"nofollow\" target=\"_blank\">Ashley.Biladeau@inizioevoke.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MTc3NCM3OTc3NDc2IzUwMDE2MzYxNQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ODE5YjQ0NTktNDgwOC00OTU1LTg3ZWItMTlkYzY5NGU4ZWM1LTUwMDE2MzYxNS0yMDI2LTExLTE5LWVu\/tiny\/Azora-Therapeutics-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LOS ANGELES, Nov. 19, 2026 (GLOBE NEWSWIRE) &#8212; Azora Therapeutics, Inc. (NASDAQ: AZR) (the \u201cCompany\u201d), a biopharmaceutical company developing treatments for serious inflammatory diseases, announced today that the Compensation Committee of its Board of Directors granted an option to purchase 40,000 shares of the Company\u2019s common stock under the Azora Therapeutics, Inc. 2026 Employment Inducement Equity Incentive Plan (the \u201c2026 Inducement Plan\u201d) to one new non-executive employee as an inducement material to such person entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The option award has an exercise price of $3.81 per share, the closing price of the Company\u2019s common stock on November 16, 2026, the effective date of grant, and has a ten-year term. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Azora Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1022784","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Azora Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Azora Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LOS ANGELES, Nov. 19, 2026 (GLOBE NEWSWIRE) &#8212; Azora Therapeutics, Inc. (NASDAQ: AZR) (the \u201cCompany\u201d), a biopharmaceutical company developing treatments for serious inflammatory diseases, announced today that the Compensation Committee of its Board of Directors granted an option to purchase 40,000 shares of the Company\u2019s common stock under the Azora Therapeutics, Inc. 2026 Employment Inducement Equity Incentive Plan (the \u201c2026 Inducement Plan\u201d) to one new non-executive employee as an inducement material to such person entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The option award has an exercise price of $3.81 per share, the closing price of the Company\u2019s common stock on November 16, 2026, the effective date of grant, and has a ten-year term. &hellip; Continue reading &quot;Azora Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-19T21:18:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MTc3NCM3OTc3NDc2IzUwMDE2MzYxNQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Azora Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2026-11-19T21:18:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/\"},\"wordCount\":367,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg4MTc3NCM3OTc3NDc2IzUwMDE2MzYxNQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/\",\"name\":\"Azora Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg4MTc3NCM3OTc3NDc2IzUwMDE2MzYxNQ==\",\"datePublished\":\"2026-11-19T21:18:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg4MTc3NCM3OTc3NDc2IzUwMDE2MzYxNQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg4MTc3NCM3OTc3NDc2IzUwMDE2MzYxNQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Azora Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Azora Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/","og_locale":"en_US","og_type":"article","og_title":"Azora Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"LOS ANGELES, Nov. 19, 2026 (GLOBE NEWSWIRE) &#8212; Azora Therapeutics, Inc. (NASDAQ: AZR) (the \u201cCompany\u201d), a biopharmaceutical company developing treatments for serious inflammatory diseases, announced today that the Compensation Committee of its Board of Directors granted an option to purchase 40,000 shares of the Company\u2019s common stock under the Azora Therapeutics, Inc. 2026 Employment Inducement Equity Incentive Plan (the \u201c2026 Inducement Plan\u201d) to one new non-executive employee as an inducement material to such person entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The option award has an exercise price of $3.81 per share, the closing price of the Company\u2019s common stock on November 16, 2026, the effective date of grant, and has a ten-year term. &hellip; Continue reading \"Azora Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-19T21:18:40+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MTc3NCM3OTc3NDc2IzUwMDE2MzYxNQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Azora Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2026-11-19T21:18:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/"},"wordCount":367,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MTc3NCM3OTc3NDc2IzUwMDE2MzYxNQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/","name":"Azora Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MTc3NCM3OTc3NDc2IzUwMDE2MzYxNQ==","datePublished":"2026-11-19T21:18:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MTc3NCM3OTc3NDc2IzUwMDE2MzYxNQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MTc3NCM3OTc3NDc2IzUwMDE2MzYxNQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azora-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Azora Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1022784","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1022784"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1022784\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1022784"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1022784"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1022784"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}